| Identification | Back Directory | [Name]
2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(8-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]phenyl]- | [CAS]
2064269-82-3 | [Synonyms]
YK-029A
2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(8-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]phenyl]- | [Molecular Formula]
C27H32N8O2 | [MOL File]
2064269-82-3.mol | [Molecular Weight]
500.6 |
| Hazard Information | Back Directory | [Uses]
YK-029A is an orally active inhibitor of mutant EGFR，targeting to both the T790M mutations (EGFRT790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity，and results tumor regression in EGFRex20ins-driven PDX models[1]. | [References]
[1] Liu B, et al. Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790?M and exon 20 insertion mutations, as a treatment for NSCLC. Eur J Med Chem. 2023 Oct 5;258:115590. DOI:10.1016/j.ejmech.2023.115590 |
|
|